The effectiveness of interferon-alpha subtypes alternation for metastasis from renal cell carcinoma

Yoshifumi Kadono, Sotaro Miwa, Takashi Shima, Hiroyuki Konaka, Atsushi Mizokami, Satoshi Yotsuyanagi, Akio Hirata, Yasukazu Takase, Toshiaki Sugata, Masayoshi Shimamura, Mikio Namiki
2012 Biomedical research  
Interferon-alpha (IFN-α) has been used in systemic treatment for metastatic renal cell carcinoma (mRCC). IFN-α has at least 14 subtypes, each of which has different biological activity. There have been reports that mRCC resistant to an IFN-α treatment responded to another IFN-α subtype. This study was performed to evaluate the effectiveness of alternation of different IFN-α subtypes for mRCC that did not respond to initial IFN-α treatment. In our department and associated institutions,
more » ... titutions, alternating therapy of IFN-α was provided for 15 initial IFN-α refractory mRCC cases from June 2005 to September 2008. Among the 15 patients, the effects of alternating IFN-α therapy were as follows: complete response (CR), 0 cases; partial response (PR), 1 case; stable disease (SD), 3 cases; progressive disease (PD), 11 cases. The response rate (CR+PR) was 7% and disease control rate (CR+PR+SD) was 27%. No severe side effects were observed in any of these cases. The PR case is still in PR 21 months after alternating IFN-α therapy. Among the three SD cases, one has continued SD for 14 months and the other for 12 months. Alternating IFN-α therapy for mRCC can be attempted even if other cytokines are not effective.
doi:10.2220/biomedres.33.323 pmid:23268955 fatcat:nzjznmhaabdcpers4ob2lekzxi